In honor of Alzheimer's and Brain Awareness Month, Tom Babic reflects on the significant milestone passed in treating those affected by Alzheimer's disease: “While not a cure, lecanemab is the first FDA-approved drug in over 20 years to show an unequivocal positive effect in subjects with Alzheimer’s disease (AD). Made possible by the collective advancement in understanding of AD’s biology, diagnostics, and treatments, lecanemab presents an opportunity for patients at the Roskamp Institute and across the US to slow the progression of their devastating disease. It’s always rewarding to hear the direct impact of Worldwide’s work on patients and their families.” https://ow.ly/Ov7V50Sr9CU
Worldwide Clinical Trials’ Post
More Relevant Posts
-
How can Worldwide support your metabolic dysfunction studies? Discover our full suite of MASH/MALD clinical development services in our fact sheet, from our core lab partnerships to global operational expertise: https://ow.ly/VyN550SwaQP
MASH/MASLD Clinical Development at Worldwide
worldwide.com
-
Want to hear about the latest cutting-edge initiatives reshaping oncology clinical trials? Discover FDA’s Project Optimus, novel study designs, and the impact of Bayesian models on drug development in our blog with Matt Cooper and james eamma: https://ow.ly/nU5150Sun6S
The Evolution of Oncology Trials: Project Optimus and Study Design Trends
worldwide.com
-
If you're in search for a bioanalytical partner to help advance your pre-clinical or clinical development program, look no further. Discover the bioanalytical difference at Worldwide! https://ow.ly/XziY50Sv484
Integrated Bioanalytical Lab in Austin, TX
worldwide.com
-
What fantastic news in the fight against obesity! Looking forward to making continuous advancements in metabolic research for conditions like NAFLD and MASLD.
Breaking News: The Treat and Reduce Obesity Act has passed the Ways and Means Committee! We extend our thanks to Chairman Congressman Jason Smith and all committee members who voted in favor. This legislation is a crucial first step in our ongoing fight against obesity, a major contributor to nonalcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD). This milestone is not just a win in the battle against obesity but also a beacon of hope for millions struggling with associated health conditions. Join us as we continue to push for meaningful change: https://alf.social/sys
-
-
Interested in the latest methods and solutions for running your oncology clinical trial? Make sure to check out james eamma’s presentation at Clinical Trials in Oncology East Coast next week, and stop by Booth 21 to speak to him about any questions you may have! https://ow.ly/k21H50Su0Jk
-
-
How do you stand out in rare neurological research? At Worldwide, we turn challenges into solutions, ensuring your trial’s success in both high- and low-competition environments by prioritizing patient voices and leveraging expert strategies. Find out how we do it in our blog: https://ow.ly/F6bs50St3xx
Elevating Your Rare Neurological Study in Any Competitive Environment
worldwide.com
-
At Worldwide, we're dedicated to enhancing your drug development journey through our people, processes, and technologies in our bioanalytical lab and clinical pharmacology unit. This commitment is embodied in our continuous improvement initiative — WorldwideEdge. Learn more: https://ow.ly/rJ9f50SsTnS
-
-
Are you ready to make an impact in rare disease research? At Worldwide, we provide bespoke, patient-centered solutions for your rare disease program, from advocacy engagement to clinical assessment and technology. Discover more about our distinct rare disease methodology and expertise today: https://ow.ly/Jhmq50SsJkL
Make Your Move into Rare Disease Research Confidently
worldwide.com
-
Radiopharmaceuticals are continuously evolving – work with a partner who specializes in this dynamic field. Discover Worldwide’s experience in radiopharmaceutical development from oncology to rare disease in our fact sheet: https://ow.ly/XYsQ50Sra23
Radiopharmaceutical Development at Worldwide Clinical Trials
worldwide.com
Chief Executive Officer at USA and International Research Inc.
1wSuch a significant milestone in Alzheimer's treatment! It's heartening to see the impact of lecanemab on patients and families.